

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: A. Asp, et al. Group Art Unit: To be assigned  
Serial Number: To be assigned Examiner: To be assigned  
Filing Date: October 3, 2001  
For: A Method of Sequencing

**First Preliminary Amendment**

Honorable Assistant Commissioner of Patents  
Box New Patent Application  
Washington, D.C. 20231

Sir:

Please consider the following amendments and remarks in connection with the prosecution of the captioned application, which is a continuation of Serial Number 09/068,783 filed February 22, 1999.

**In the Claims:**

Please cancel claims 1-10 and 13, without prejudice.

At page 10, line 1:

**[CLAIMS]**

**What is claimed is:**

**In the Specification**

At page 1, line 1, please add the following:

-- This application is a continuation of United States patent application number 09/068,783 having a filing date of February 22, 1999, which is a filing under 35 U.S.C. 371 claiming priority to international patent application number PCT/SE96/01464, the entire disclosure of which is incorporated herein by reference. --

At page 5, line 36, immediately prior to the section entitled “Example :”, please insert the following:

- - Brief Description of the Figures

Figure 1 presents a schematic presentation of the method of this invention, illustrating

- a) biotin incorporation at the end of each strand of the polynucleotide;
- b) immobilization of biotinylated strands to a solid support; and
- c) annealing of a blue and a red labeled sequencing primer to the strands.

Figure 2 presents the results obtained with the red label and the blue label in the example. - -

Please amend the paragraph at page 6, lines 22-23, as follows:

Primer: 5' – Biotin – GCT TCC GGC TCG TAT GTT GTG TG-3' (SEQ ID NO 1)

5' – Biotin – AAA GGG GGA TGT GCT GCA AGG CG-3' (SEQ ID NO 2)

At the end of the written description, before the claims, please insert the Sequence Listing attached hereto.

**In the Abstract**

After the claims, on a separate sheet, please insert the following abstract:

**-- Abstract**

A method of analyzing a sequence of a polynucleotide of interest, comprising the steps of: a) incorporating one member of a specific binding pair at the end of each strand of a double stranded polynucleotide of interest, the number being of the same type for both strands, b) immobilizing both strands of the polynucleotide to a solid support provided with the other member of the specific binding pair, c) annealing sequencing primers to the immobilized strands, d) sequencing both strands by the chain termination method. The polynucleotide of interest is preferably amplified before or in connection with step a) and most preferably by polymerase chain reaction extension. The invention also comprises a kit for use in analyzing the sequence of a polynucleotide of interest. --


**Remarks**

Claims 1-13 were filed in the parent to the captioned application; Applicants have cancelled claims 1-10 and 13, without prejudice. Claims 11 and 12 remain.

Applicants respectfully submit that the amendments are fairly based on the specification, and respectfully request their entry. Applicants believe that the claims are in allowable form, and earnestly solicit their allowance.

Should the Examiner have any questions with respect to the foregoing, please contact Applicants' counsel at the telephone number below.

Respectfully submitted,



Royal N. Ronning, Jr. 32,529  
Attorney for Applicants

Amersham Pharmacia Biotech, Inc.  
800 Centennial Avenue  
P.O. Box 1327  
Piscataway, New Jersey 08855-1327

Tel: (732) 457-8423  
Fax: (732) 457-8463

SEQUENCE LISTING

<110> Asp, Allan  
Carstenius, Peder

<120> A Method of Sequencing

<130> Pha1626

<140> To be assigned  
<141> 2001-10-03

<150> 09/068,783  
<151> 1999-02-22

<150> SE 9504099-4  
<151> 1995-11-16

<150> PCT/SE96/01464  
<151> 1996-11-13

<160> 2

<170> PatentIn Ver. 2.1

<210> 1  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 1  
gcttccggct cgtatgttgt gtg

23

<210> 2  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 2

aaaggggat gtgctgcaag gcg

23